Cargando…
Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study in Taiwan, 2010–2016
BACKGROUND: Only 5-fluorouracil (5-FU), cisplatin, and gemcitabine have been reimbursed for metastatic pancreatic cancer (mPC) treatment in Taiwan since 2003. It is uncertain whether the reimbursement of S-1 in June 2014 might change the treatment pattern and improve the survival of mPC patients in...
Autores principales: | Chou, Wen-Chi, Chen, Yen-Yang, Hung, Chia-Yen, Chen, Jen-Shi, Lu, Chang-Hsien, Chang, Pei-Hung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421872/ https://www.ncbi.nlm.nih.gov/pubmed/30936744 http://dx.doi.org/10.2147/CMAR.S196300 |
Ejemplares similares
-
Survival and Treatment of Lung Cancer in Taiwan between 2010 and 2016
por: Chang, Yen-Jung, et al.
Publicado: (2021) -
Effect of S‐1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7‐year multicenter observational cohort study in Taiwan
por: Lai, Hsiang‐Lan, et al.
Publicado: (2019) -
Bacterial diversity among four healthcare-associated institutes in Taiwan
por: Chen, Chang-Hua, et al.
Publicado: (2017) -
Incidence Patterns of Primary Bone Cancer in Taiwan (2003–2010): A Population-Based Study
por: Hung, Giun-Yi, et al.
Publicado: (2014) -
Epidemiology and risk factors of Japanese encephalitis in Taiwan, 2010–2022
por: Hsu, Jen-Yu, et al.
Publicado: (2023)